DMT

From BurnZero
Psychedelic SETI.png

N, N-Dimethyltryptamine (DMT) is a psychedelic that induces changes in consciousness which in intensity surpass most other categories of psychoactive drugs. Users consistently experience vivid visual imagery accompanying what is frequently described as a sense of “breaking through” into another world or dimension. These experiences are often deemed profound and have the potential to challenge beliefs about the nature of reality and consciousness.

Pharmacology

DMT has overwhelmingly rapid, short‐acting effects: when administered intravenously through a bolus injection, subjective and physical effects peak within two minutes of administration and quickly subside thereafter, fully resolving after 20‐30 minutes.

Repeated psychedelic doses of IV bolus DMT injections have been found not to produce any psychological tolerance. This plus the short time‐course of its action makes DMT unique among classic serotonergic psychedelics, and suitable for continuous IV administration.

DMT is metabolized by MAO-A and that blocking this enzyme with harmala alkaloids results in either greater intensity and/or duration of DMT’s action.

It is thought like with other psychedelics its main action comes from 5HT2A agonism, however it has been shown that DMT has a unique action on Sigma 1 receptors[1].

Psychedelic SETI

Some studies suggest that our brains naturally produce DMT, and those who have used it frequently report variations on the same theme: entering what appears to be another plane or dimension, complete with its own ethereal beings, sometimes referred to as "machine elves," who are there to welcome them. DMTx, Medicinal Mindfulness hopes to extend the trip through IV drip to hours or perhaps days, which, they believe, would extend its duration on the other side for an indefinite amount of time.

References

  1. N,N-Dimethyltryptamine attenuates spreading depolarization and restrains neurodegeneration by sigma-1 receptor activation in the ischemic rat brain. Szabó a, Viktória É. Varga a. Neuropharmacology. Volume 192, 1 July 2021, 108612. https://www.sciencedirect.com/science/article/pii/S0028390821001660

Share your opinion